US Patent

US11759503 — Compositions of GLP-1 peptides and preparation thereof

Formulation · Assigned to Novo Nordisk AS · Expires 2033-03-15 · 7y remaining

Vulnerability score 33/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical compositions made from two types of granules, one containing a specific acid salt and the other containing a GLP-1 peptide.

USPTO Abstract

The invention relates to pharmaceutical compositions comprising a first type of granules and a second type of granules, wherein said first type of granules comprises a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and no GLP-1 peptide, and wherein said second type of granules comprises a GLP-1 peptide and no salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, as well as the intermediate granules, processes for the preparation of the granules and compositions, and use thereof in medicine.

Drugs covered by this patent

Patent Metadata

Patent number
US11759503
Jurisdiction
US
Classification
Formulation
Expires
2033-03-15
Drug substance claim
No
Drug product claim
Yes
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.